SAFETY: NRTX-1001 continues to be well-tolerated at both high and low doses with no adverse events attributed to the cell therapy. –NEXT STEPS: Phase 3 EPIC trial planned to start enrolling in 2H 2025 ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon ...

One called streptothricin was isolated in the 1940s, drawing attention for its potential in treating infections caused by what are known as gram-negative bacteria. Unlike gram-positive bacteria, these ...

First, gram-negative bacteria have a thin cell wall that is about 1.5 to 10 nanometers across, whereas gram-positive bacteria have a thick cell wall measuring about 20 to 80 nanometers.

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human Phase I trial using a chimeric antigen receptor (CAR) T cell therapy developed by ...

A team led by Paul Hergenrother at the University of Illinois Urbana-Champaign has discovered a new antibiotic that exclusively targets gram-negative bacteria and avoids wiping out the ecosystem ...

It has activity against a wide range of gram-positive and gram-negative pathogens. The EAGLE-2 and EAGLE-3 phase 3 RCTs compared gepotidacin with nitrofurantoin for uncomplicated UTIs (uUTIs ...

One such useful classification – if a bacterium is gram positive or gram negative - is based on the structure of bacterial cell walls. Gram positive bacteria are surrounded by a single thick ...

HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a clinical-stage biotechnology company, today announced positive clinical trial data demonstrating long-term safety and efficacy of InGeneron’s cell ...